Exhibit 99.1

Contact:
Rob Seim		Omnicell, Inc.

Chief Financial Officer		590 East Middlefield Road

800-850-6664, ext. 6478		Mountain View, CA 94043

rob.seim@omnicell.com

Omnicell Achieves Record Revenues and Earnings in 2013

Extends Four-Year Trajectory of Company Growth

MOUNTAIN VIEW, Calif. — February 4, 2014— Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its fourth quarter and year ended December 31, 2013.

GAAP results: Revenue for the fourth quarter of 2013 was $105.8 million, up $11.7 million or 12.5% from the third quarter of 2013, and up $15.6 million or 17.3% from the fourth quarter of 2012. Revenue for the year ended December 31, 2013 was $380.6 million, up $66.6 million or 21.2% from the year ended December 31, 2012.

Fourth quarter 2013 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $6.8 million, or $0.19 per diluted share. This compares to net income of $7.8 million, or $0.21 per diluted share, in the third quarter of 2013 and net income of $5.5 million, or $0.16 per diluted share, in the fourth quarter of 2012. For the year ended December 31, 2013, net income was $24.0 million, or $0.67 per diluted share. This compares to net income of $16.2 million, or $0.47 per diluted share, for the year ended December 31, 2012.

Non-GAAP results: Non-GAAP net income was $10.5 million for the fourth quarter of 2013, or $0.29 per diluted share. Non-GAAP net income for the fourth quarter excludes $2.7 million of stock-based compensation expense, $1.0 million ($0.6 million net of the $0.4 million tax effect) of amortization expense for all intangible assets associated with acquisitions made by Omnicell in 2012 and earlier and $0.6 million ($0.4 million net of the $0.2 million tax effect) of non-recurring charges incurred in connection with the previously announced agreement to acquire Surgichem Limited, a wholly-owned subsidiary of Bupa Care Homes plc. This compares to non-GAAP net income of $8.6 million, or $0.25 per diluted share, for the fourth quarter of 2012. Non-GAAP net income for the fourth quarter of 2012 excluded $2.4 million of stock-based compensation expense and $1.1 million ($0.7 million net of the $0.4 million tax effect) of amortization expense for all intangible assets associated with acquisitions made by Omnicell in 2012 and earlier. Fourth quarter results compare to non-GAAP net income of $11.3 million, or $0.31 per diluted share, for the third quarter of 2013. Non-GAAP net income for the third quarter excluded $2.8 million of stock-based compensation expense and $1.1 million ($0.8 million net of $0.3 million tax effect) of amortization expense for all intangible assets associated with acquisitions made by Omnicell in 2012 and earlier.

For the year ended December 31, 2013, non-GAAP net income was $38.6 million, or $1.08 per diluted share. Non-GAAP net income for the year ended December 31, 2013 excludes $11.2 million of stock-based compensation expense, $0.7 million ($0.4 million net of $0.3 million tax effect) of reorganization costs incurred in the first quarter of 2013 related to the integration of MTS Medication Technologies, $0.6 million ($0.4 million net of the $0.2 million tax effect) of non-recurring charges incurred in connection with the previously announced agreement to acquire Surgichem Limited, a wholly-owned subsidiary of Bupa Care Homes plc and $4.2 million ($2.7 million net of the $1.5 million tax effect) of amortization expense for all intangible assets associated with acquisitions made by Omnicell in 2012 and earlier. For the year ended December 31, 2012, non-GAAP net income was $29.8 million, or $0.87 per diluted share. Non-GAAP net income for the year ended December 31, 2012 excluded $9.2 million of stock-based compensation expense, $4.9 million of acquisition transaction and integration costs ($2.9 million net of the $2.0 million tax effect), and $2.7 million ($1.6 million net of the $1.1 million tax effect) of amortization expense for all intangible assets associated with acquisitions made by Omnicell in 2012 and earlier.

About Omnicell

For over 20 years, the mission of Omnicell (NASDAQ: OMCL) has been creating new efficiencies to help improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

Since 1992, more than 2,800 Acute Care customers worldwide have utilized Omnicell’s medication automation, supply chain and analytics solutions to enable them to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Non-Acute Care solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions that can help reduce costly hospital readmissions and enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

For more information about Omnicell, please visit www.omnicell.com.

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside Omnicell’s control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such statements include, but are not limited to Omnicell’s growth and the success of Omnicell’s strategy. Risks that contribute to the uncertain nature of the forward-looking statements include our ability to take advantage of the growth opportunities in medication management across the spectrum of healthcare settings from long term care to home care, unfavorable general economic and market conditions, risks to growth and acceptance of our products and services, including competitive conversions, and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, and the ability of the company to improve sales productivity to grow product backlog and to develop new products and integrate acquired companies. These and other risks and uncertainties are described more fully in Omnicell’s most recent filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Omnicell undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell’s GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share. Additionally, we calculate Adjusted EBITDA (another non-GAAP measure) by means of adjustments to GAAP Net Income. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, net income per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell’s performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income and non-GAAP net income per diluted share are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period to period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of Accounting Standards Codification (ASC) 718. We recognize equity plan-related compensation expenses, which represent the fair value of all share-based payments to employees, including grants of employee stock options, as required under ASC 718, “Stock Compensation” as non-GAAP adjustments in each period.

b) Reorganization costs. During the year ended December 31, 2013, we recorded $0.7 million of reorganization costs related to our Non-Acute Care segment ($0.4 million net of the $0.3 million tax effect). This charge is not expected to be recurring and, as such, the financial impact is excluded from our non-GAAP results.

c) Acquisition-related transaction and integration expenses. In connection with the previously announced agreement to acquire Surgichem Limited, we recorded $0.6 million of pre-acquisition costs ($0.4 million net of $0.2 million tax effect) in the fourth quarter of 2013. In the second quarter of 2012, we recorded $4.9 million of acquisition-related transaction and integration costs ($2.9 million net of the $2.0 million tax effect). These charges are not expected to be recurring and, as such, the financial impact of these costs is excluded from our non-GAAP results.

d) Intangible assets amortization from business acquisitions. We excluded from our non-GAAP results the intangible assets amortization expense resulting from the MTS acquisition as well as earlier Omnicell acquisitions. This impacts the fourth quarter of fiscal 2013 non-GAAP results by $1.0 million ($0.6 million net of $0.4 million tax effect) and December 31, 2013 year-to-date non-GAAP results by $4.2 million ($2.7 million net of $1.5 million tax effect). This impacted December 31, 2012 fourth quarter results by $1.1 million ($0.7 million net of $0.4 million tax effect) and December 31, 2012 year-to-date results by $2.7 million ($1.6 million net of the $1.1 million tax effect).These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell’s management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense related to ASC 718 is excluded from our non-GAAP financial measures:

Omnicell, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share data, unaudited)

	Three Months Ended								Year Ended
	December 31, 2013			September 30, 2013		December 31, 2012			December 31, 2013			December 31, 2012
Revenues:
Product	$	86,864		$	75,508	$	72,415		$	307,189		$	247,654
Services and other revenues	18,886			18,531		17,754			73,396			66,373
Total revenue	105,750			94,039		90,169			380,585			314,027

Cost of revenues:
Cost of product revenues	41,187			33,977		32,837			144,997			112,369
Cost of services and other revenues	7,939			8,022		7,956			32,189			31,070
Total cost of revenues	49,126			41,999		40,793			177,186			143,439

Gross profit	56,624			52,040		49,376			203,399			170,588
Operating expenses:
Research and development	7,440			6,561		6,188			29,105			23,726
Selling, general and administrative	38,129			34,762		33,354			138,995			119,736
Total operating expenses	45,569			41,323		39,542			168,100			143,462
Income from operations	11,055			10,717		9,834			35,299			27,126
Other income and (expense), net	(136		)	25		(108		)	(270		)	(51		)
Income before provision for income taxes	10,919			10,742		9,726			35,029			27,075
Provision for income taxes	4,096			2,987		4,194			11,050			10,897
Net income	$	6,823		$	7,755	$	5,532		$	23,979		$	16,178

Net income per share:
Basic	$	0.19		$	0.22	$	0.17		$	0.69		$	0.49
Diluted	$	0.19		$	0.21	$	0.16		$	0.67		$	0.47

Weighted average shares outstanding:
Basic	35,495			35,133		33,282			34,736			33,307
Diluted	36,610			36,190		34,128			35,774			34,213

Omnicell, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

	December 31,		December 31,
	2013		2012
	(unaudited)		(1)

ASSETS
Current assets:
Cash and cash equivalents	$	104,531	$	62,313
Accounts receivable, net	58,597		55,116
Inventories	31,457		26,903
Prepaid expenses	18,883		15,392
Deferred tax assets	12,635		11,860
Other current assets	7,674		9,172
Total current assets	233,777		180,756

Property and equipment, net	35,254		34,107
Non-current net investment in sales-type leases	11,485		13,228
Goodwill	111,343		111,407
Other intangible assets	81,602		85,550
Non-current deferred tax assets	1,102		993
Other assets	17,938		15,778
Total assets	$	492,501	$	441,819

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	16,471	$	18,255
Accrued compensation	20,266		11,613
Accrued liabilities	13,746		11,988
Deferred service revenue	22,626		20,449
Deferred gross profit	19,957		20,772
Total current liabilities	93,066		83,077

Non-current deferred service revenue	17,763		19,892
Non-current deferred tax liabilities	28,162		26,491
Other long-term liabilities	5,176		4,809
Total liabilities	144,167		134,269

Stockholders’ equity:
Total stockholders’ equity	348,334		307,550

Total liabilities and stockholders’ equity	$	492,501	$	441,819

(1) Information derived from our December 31, 2012 audited Consolidated Financial Statements.

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(In thousands, except per share data, unaudited)

	Three months ended
	December 31, 2013					September 30, 2013					December 31, 2012
	Net income			Net income per share- diluted		Net income			Net income per share- diluted		Net income			Net income per share- diluted
GAAP	$	6,823		$	0.19	$	7,755		$	0.21	$	5,532		$	0.16
Non-GAAP adjustments:
Pre-acquisition, transaction and integration costs for acquisitions	605					—					—
Amortization of intangible assets acquired by acquisition	1,049					1,060					1,057
Subtotal pretax adjustments	1,654					1,060					1,057
Income tax effect of non-GAAP adjustments (a)	(662		)			(295		)			(423		)
Subtotal after-tax adjustments	992					765					634
ASC 718 share-based compensation adjustment (b)
Gross profit	287					325					236
Operating expenses	2,442					2,485					2,197
Total after-tax adjustments	3,721			0.10		3,575			0.10		3,067			0.09

Non-GAAP	$	10,544		$	0.29	$	11,330		$	0.31	$	8,599		$	0.25

(a) Tax effects are calculated using the effective tax rates for the respective periods presented.

(b) This adjustment reflects the accounting impact of non-cash stock-based compensation expense related to the impact of ASC 718 for the periods shown.

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(In thousands, except per share data, unaudited)

	Year Ended
	December 31, 2013					December 31, 2012
	Net income			Net income per share- diluted		Net income			Net income per share- diluted
GAAP	$	23,979		$	0.67	$	16,161		$	0.47
Non-GAAP adjustments:
Business acquisition costs
Reorganization costs (a)	732					—
Pre-acquisition, transaction and integration costs for acquisitions (b)	605					4,855
Amortization of intangible assets acquired by acquisition (c)	4,229					2,672
Subtotal pretax adjustments	5,566					7,527
Income tax effect of non-GAAP adjustments (d)	(2,057		)			(3,086		)
Subtotal after-tax adjustments	3,509					4,441

ASC 718 share-based compensation adjustment (e)
Gross profit	1,241					1,012
Operating expenses	9,911					8,202
Total after tax adjustments	14,661			0.41		13,655			0.40

Non-GAAP	$	38,640		$	1.08	$	29,816		$	0.87

(a) This adjustment is for reorganization costs related to our Non-Acute Care segment for the twelve months ended December 31, 2013.

(b) This adjustment is for the incurrence of pre-acquisition costs related to our previously announced agreement to acquire Surgichem Limited in December 2013 and transaction and integration costs related to our acquisition of MTS in May 2012.

(c) Beginning with the second quarter of 2012, we are recognizing the amortization expense resulting from certain intangible assets recorded from business acquisitions as a non-GAAP adjustment, including MTS and prior acquisitions.

(d) Tax effects are calculated using the effective tax rates for the respective periods presented.

(e) This adjustment reflects the accounting impact of non-cash stock-based compensation expense related to the impact of ASC 718 for the periods shown.

Omnicell, Inc.

Calculation of Adjusted EBITDA (1)

(In thousands, unaudited)

	Three Months Ended								Year ended
	December 31, 2013		September 30, 2013			December 31, 2012			December 31, 2013		December 31, 2012

GAAP net income	$	6,823	$	7,755		$	5,532		$	23,979	$	16,161
Add back:
ASC 718 stock compensation expense	2,729		2,810			2,433			11,152		9,214
Reorganization costs	—		—			—			732		—
Transaction and integration costs for acquisitions, pre-tax	605		—			—			605		4,855
Interest	7		(14		)	(2		)	92		(48		)
Depreciation and amortization expense	4,633		4,488			4,077			18,365		13,323
Income tax expense	4,096		2,987			4,168			11,050		10,871
Non-GAAP adjusted EBITDA (1)	$	18,893	$	18,025		$	16,208		$	65,975	$	54,376

(1) Defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including stock compensation expense, per ASC 718, as well as excluding certain non-GAAP adjustments. The non-GAAP adjustments for the twelve months ended December 31, 2013 and 2012 exclude transaction and integration costs for MTS, acquired in May 2012.